1-3 of 3
Peter Cassileth
Close
Sort by
Journal Articles

A 3,239 -Patient Combined Eastern Cooperative Oncology Group (ECOG), M.D. Anderson Cancer Center (MDA) Analysis of the Effect of CR vs. Responses < CR on Long-Term Survival in Newly-Diagnosed AML Treated with Ara-C-Containing Regimens: Implications for Targeted Drug Development.

Elihu Estey, MD, Zhuoxin Sun, MD, Jacob Rowe, MD, Stefan Faderl, MD, Peter Cassileth, MD, George Sartiano, MD, Anthony Tartaglia, MD, Guillermo Garcia-Manero, MD, Larry Cripe, MD, John Bennett, MD, Hagop Kantarjian, MD, Martin Tallman, MD
Journal: Blood
Blood (2007) 110 (11): 298.
https://doi.org/10.1182/blood.V110.11.298.298
Published: 2007
Journal Articles

Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493)

Clinical Trials & Observations
Joseph A. Sparano, Edie Weller, Tipu Nazeer, Thomas Habermann, Ann E. Traynor, Jane Manalo, Peter Cassileth
Journal: Blood
Blood (2002) 100 (5): 1634–1640.
https://doi.org/10.1182/blood.V100.5.1634.h81702001634_1634_1640
Published: 2002
Journal Articles

Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin

Clinical Trials & Observations
Ian W. Flinn, Kenneth J. Kopecky, M. Kathryn Foucar, David Head, John M. Bennett, Robert Hutchison, William Corbett, Peter Cassileth, Thomas Habermann, Harvey Golomb, Kanti Rai, Elizabeth Eisenhauer, Frederick Appelbaum, Bruce Cheson, Michael R. Grever
Journal: Blood
Blood (2000) 96 (9): 2981–2986.
https://doi.org/10.1182/blood.V96.9.2981
Published: 2000